Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Jiajun ZhangWeihai LiuChangye ZouZhiqiang ZhaoYuanying LaiZhi ShiXianbiao XieGang HuangYongqian WangXuelin ZhangZepei FanQiao SuJunqiang YinJingnan ShenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Super-enhancer-associated genes contribute to the malignant potential of osteosarcoma, and selectively targeting super-enhancer-associated oncogenes with the specific CDK7 inhibitor THZ2 might be a promising therapeutic strategy for patients with osteosarcoma.